Loading…
Advances in Immunotherapy for Glioblastoma Multiforme
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults. Patients with GBM have poor outcomes, even with the current gold-standard first-line treatment: maximal safe resection combined with radiotherapy and temozolomide chemotherapy. Accumulating evidence suggests th...
Main Authors: | Huang, Boyuan, Zhang, Hongbo, Gu, Lijuan, Ye, Bainxin, Jian, Zhihong, Stary, Creed, Xiong, Xiaoxing |
---|---|
Format: | Online Article Text |
Language: | English |
Published: |
Hindawi Publishing Corporation
2017
|
Subjects: | |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5337363/ https://www.ncbi.nlm.nih.gov/pubmed/28299344 http://dx.doi.org/10.1155/2017/3597613 |
Similar Items
-
Current Immunotherapies for Glioblastoma Multiforme
by: Huang, Boyuan, et al.
Published: (2021) -
Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
by: Ye, Baixin, et al.
Published: (2017) -
Extracellular vesicle-derived miRNA as a novel regulatory system for bi-directional communication in gut-brain-microbiota axis
by: Zhao, Liang, et al.
Published: (2021) -
Single-Cell Sequencing Technology in Oncology: Applications for Clinical Therapies and Research
by: Ye, Baixin, et al.
Published: (2016) -
Advances in immunotherapy for glioblastoma multiforme
by: Mahmoud, Ahmad Bakur, et al.
Published: (2022)